INVACARE CORPORATION (NYSE:IVC) Files An 8-K Regulation FD Disclosure

On April 7, 2017, Invacare Corporation (the Company) mailed a
letter from the Chairman, President and Chief Executive Officer to
the Companys shareholders, as part of the Companys 2016 annual
report to shareholders. A copy of the letter to shareholders is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The letter to shareholders contains forward-looking statements
within the meaning of the Safe Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Terms such as will,
should, could, plan, intend, expect, continue, believe and
anticipate, as well as similar comments, denote forward-looking
statements that are subject to inherent uncertainties that are
difficult to predict. Actual results and events may differ
significantly from those expressed or anticipated as a result of
risks and uncertainties, which include, but are not limited to, the
following: adverse effects of the companys consent decree of
injunction with the U.S. Food and Drug Administration (FDA),
including but not limited to, compliance costs, limitations on the
production and/or distribution of the company’s products,
inability to bid on or win certain contracts, unabsorbed capacity
utilization, including fixed costs and overhead, or limitations on
the companys ability to design new power wheelchairs at its
Corporate and Taylor Street facilities; any circumstances or
developments that might delay or adversely impact FDA’s acceptance
of the experts updated report on the remediation of specified
design history files, FDA’s acceptance of the third, most
comprehensive expert certification audit report, FDA’s acceptance
of the company’s own written report as required by the consent
decree, or FDA’s inspection of the company’s quality systems at
the Elyria, Ohio, facilities impacted by the consent decree,
including any possible failure to comply with the consent decree or
FDA regulations, any requirement to perform additional remediation
activities or further resultant delays in receipt of FDA’s written
notification to resume operations; regulatory proceedings or the
company’s failure to comply with regulatory requirements or
receive regulatory clearance or approval for the company’s
products or operations in the United States or abroad; adverse
effects of regulatory or governmental inspections of company
facilities at any time and governmental enforcement actions;
circumstances or developments that may make the company unable to
implement or realize the anticipated benefits, or that may increase
the costs, of its current business initiatives; product liability
or warranty claims; product recalls, including more extensive
warranty or recall experience than expected; the failure or refusal
of customers or healthcare professionals to sign verification of
medical necessity (VMN) documentation or other certification forms
required by the exceptions to FDA consent decree; possible adverse
effects of being leveraged, including interest rate or event of
default risks; exchange rate fluctuations, particularly in light of
the relative importance of the company’s foreign operations to its
overall financial performance and including the existing and
potential impacts from the Brexit referendum; potential impacts of
the new United States administrations policies, and any legislation
or regulations that may result from those policies, such as
possible border-adjusted taxes on imported goods; legal actions,
including adverse judgments or settlements of litigation or claims
in excess of available insurance limits; adverse changes in
government and other third-party payor reimbursement levels and
practices both in the U.S. and in other countries (such as, for
example, more extensive pre-payment reviews and post-payment audits
by payors, or the continuing impact of the Medicare National
Competitive Bidding program); ineffective cost reduction and
restructuring efforts or inability to realize anticipated cost
savings or achieve desired efficiencies from such efforts; delays,
disruptions or excessive costs incurred in facility closures or
consolidations; tax rate fluctuations; additional tax expense or
additional tax exposures, which could affect the company’s future
profitability and cash flow; inability to design, manufacture,
distribute and achieve market acceptance of new products with
greater functionality or new product platforms that deliver the
anticipated benefits; consolidation of health care providers; lower
cost imports; uncollectible accounts receivable; difficulties in
implementing/upgrading Enterprise Resource Planning systems; risk
of cybersecurity attack, data breach or data loss and/or delays in
or inability to recover or restore data and IT systems; risks
inherent in managing and operating businesses in many different
foreign jurisdictions; decreased availability or increased costs of
materials which could increase the company’s costs of producing or
acquiring the company’s products, including possible increases in
commodity costs or freight costs; heightened vulnerability to a
hostile takeover attempt or other shareholder activism; provisions
of Ohio law or in the company’s debt agreements, charter documents
or other agreements that may prevent or delay a change in control,
as well as the risks described from time to time in the company’s
reports as filed with the Securities and Exchange Commission.
Except to the extent required by law, the company does not
undertake and specifically declines any obligation to review or
update any forward-looking statements or to publicly announce the
results of any revisions to any of such statements to reflect
future events or developments or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.